Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition
Retrieved on:
Monday, December 13, 2021
Therapy, Death, Platelet, ALK2, MDS, RBC, TI, Haematopoiesis, LTB, KROS, Fatigue, Thrombopoiesis, The Witch: Part 1. The Subversion, Serum, American Society of Hematology, HTB, Research, Inflammation, Solar cycle 1, Nausea, Reticulocyte, Exposition, Disease, RS, Model, GLOBE, Lists of diseases, Acute myeloid leukemia, ASH, Treatment, Breathe Me, Erythropoiesis, Society, Diarrhea, Cohort, Medical device, Pharmaceutical industry, Medical imaging, Residential care, Anemia, Patient, Hematology
In addition, Keros announced preclinical data evaluating ALK2 inhibition as a potential treatment option for anemia of inflammation.
Key Points:
- In addition, Keros announced preclinical data evaluating ALK2 inhibition as a potential treatment option for anemia of inflammation.
- Enrollment was balanced approximately one-to-one between patients that did not have ring sideroblasts (non-RS) and patients that have ring sideroblasts (RS positive).
- The most commonly reported treatment-emergent adverse events were nausea, fatigue, diarrhea and dyspnea, none of which were deemed related to study drug.
- ET, to discuss the additional results from the ongoing Phase 2 clinical trial of KER-050 presented at the 2021 ASH Annual Meeting and Exposition.